- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Systemic corticosteroid monotherapy has no benefit for acute rhinosinusitis
Systemic corticosteroid monotherapy of prednisone is not effective for patients with acute rhinosinusitis, according to a study published in the August 7 issue of the Canadian Medical Association Journal.
Systemic corticosteroid monotherapy of prednisone is not effective for patients with acute rhinosinusitis, according to a study published in the August 7 issue of the Canadian Medical Association Journal.
Roderick P. Venekamp and colleagues conducted a block-randomized, double-blind, placebo-controlled clinical trial at 54 primary care practices in the Netherlands over a span of 3 years.
Of the 174 patients included in the trial, those with facial pain or pressure on day 7 were 62.5% in the prednisone group and 55.8% in the placebo group. “The groups were similar with regard to the decrease over time in the proportion of patients with total symptoms and health-related quality of life,” the researchers wrote.
“Our study results indicate that the anti-inflammatory effect of corticosteroids seems to be of no benefit in the broad population of patients with clinically diagnosed acute rhinosinusitis,” the researchers added.
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
